Mar 09, 2022 / 02:10PM GMT
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good morning, and welcome to the Organon session of Cowen's 42nd Annual Healthcare Conference. We're very pleased to have with us the top management of Organon, one of the most unique and exciting and emerging companies in the biopharma space. So we're very pleased to have you with us at our conference.
Representing the company is Kevin Ali, who is the CEO; Matthew Walsh, who is the CFO; Sandra Milligan, who is the Head of R&D; and Jen Halchak, who is the Head of Investor Relations.
Questions and Answers:
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research AnalystSo with that, I'd like just to dive right into the Q&A. We'll centermost of the companies on the women's health area -- most of the questions on the women's health area, but we may sprinkle in a few others as well.
So let's start out with your most important product, that being NEXPLANON. Q4 for NEXPLANON was the highest quarter
Trustpilot
